Our broad-based transaction experience extends across a range of situations, industries and enterprise values
Categories
Year
Type
Industry
Announced: January 27, 2026Value: $4.0 billionStatus: ClosedExclusive financial advisor to the Republic of Ecuador on its Eurobond issuance
Announced: January 16, 2026Value: $1 billionStatus: PendingFinancial advisor to SEEQC on its agreement to combine with Allegro Merger Corp, supported by a $65 million PIPE financing
Announced: June 11, 2026Value: $142 millionStatus: ClosedPassive co-manager on Forbright's IPO pricing
Announced: June 9, 2026Value: $10.6bnStatus: PendingCenterview partners as exclusive financial advisor to Nuvalent
Announced: June 2, 2026Value: £337mmStatus: PendingCenterview as exclusive financial advisor to Wiley on their acquisition of Emerald from Cambridge Information Group
Announced: June 1, 2026Value: Up to $2.65bnStatus: PendingExclusive financial advisor to Edgewise on its sale of Sevasemten to Servier
Announced: June 1, 2026Value: $1.5bnStatus: PendingFinancial Advisor to Motorola Solutions on their acquisition of D-Fend Solutions
Announced: May 28, 2026Status: PendingExclusive Financial Advisor to Tractor Supply Company on their acquisition of VIP Petcare
Announced: May 26, 2026Value: Up to $1.5bnStatus: PendingFinancial advisor to Curevo on its sale to Eli Lilly
Announced: May 21, 2026Value: $69bnStatus: PendingCenterview served as lead financial advisor to Equity Residential in their merger with AvalonBay Communities
Announced: April 29, 2026Value: Up to $900mmStatus: PendingFinancial Advisor on its sale to Teva
Announced: April 29, 2026Value: $1.9bnStatus: PendingFinancial Advisor to KalVista on its sale to Chiesi
Announced: April 17, 2026Value: Up to $1.15bnStatus: PendingCenterview as exclusive financial advisor to Neurona on its sale to UCB
Announced: April 7, 2026Value: Up to $5.0bnStatus: PendingFinancial advisor to Gilead on its acquisition of Tubulis
Announced: April 6, 2026Value: $2.9bnStatus: PendingLead financial advisor to Soleno on its sale to Neurocrine
Announced: April 2, 2026Status: PendingCenterview as sole financial advisor to TMRW on their merger and Series E
Announced: April 1, 2026Status: PendingCenterview as financial advisor to Aptiv in its separation of Versigent